Description

Retatrutide (also known as LY3437943 or “triple G”) is an investigational synthetic peptide. It is a first-in-class triple hormone receptor agonist that simultaneously activates three key receptors involved in metabolic regulation: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG or glucagon receptor). This multi-pathway approach sets it apart from dual agonists like tirzepatide (Mounjaro/Zepbound) or single GLP-1 agonists like semaglutide (Ozempic/Wegovy), potentially offering enhanced effects on appetite, fat metabolism, insulin sensitivity, and energy expenditure.

Retatrutide is a 39-amino-acid peptide engineered from a GIP backbone with modifications (e.g., non-coded amino acids like Aib for stability and a fatty diacid chain for extended half-life), allowing once-weekly subcutaneous injection. It is not FDA-approved (as of March 2026) and remains in late-stage clinical development under the TRIUMPH Phase 3 program, with multiple trials ongoing or recently reporting data. Eli Lilly anticipates completing key readouts throughout 2026, with potential FDA submission in late 2026 or early 2027, and approval possibly in 2027–2028 if successful.

Key Features and Mechanism of Action

Retatrutide mimics and amplifies the effects of three gut-derived hormones:

• GLP-1 receptor activation: Suppresses appetite, slows gastric emptying (promoting fullness), enhances glucose-dependent insulin secretion, and reduces glucagon release post-meal.
• GIP receptor activation: Boosts insulin release, improves insulin sensitivity, and supports lipid metabolism/adipose tissue function.
• Glucagon receptor activation: Increases energy expenditure, promotes fat breakdown (lipolysis), and enhances hepatic glucose production in a balanced way to avoid hyperglycemia.

This synergistic “triple action” leads to greater appetite control, fat burning, improved glycemic control, and metabolic efficiency compared to single- or dual-agonist therapies.

Potential Benefits

From Phase 2 and emerging Phase 3 trials (e.g., TRIUMPH series):

• Significant Weight Loss: Dose-dependent reductions, with up to 24.2% average body weight loss at 48 weeks (12 mg dose) in Phase 2 obesity trials, and 28.7% (about 71.2 lbs or 32.3 kg) over 68 weeks in the Phase 3 TRIUMPH-4 trial (obesity/overweight with knee osteoarthritis, no diabetes). Higher percentages achieved ≥15–20% loss in most participants on top doses.
• Metabolic Improvements: Reductions in HbA1c (blood sugar control), better lipid profiles, and potential benefits for type 2 diabetes, NAFLD, and cardiovascular risk.
• Other Areas: Relief from osteoarthritis pain and improved physical function (TRIUMPH-4), plus emerging data on sleep apnea, kidney outcomes, and CV events in ongoing trials.

Administration and Dosing

• Route: Once-weekly subcutaneous injection (similar to other incretin-based therapies).
• Typical Trial Dosing (escalated gradually to minimize side effects): Starting low (e.g., 2–4 mg), titrating to maintenance doses of 4 mg, 9 mg, or 12 mg weekly.
• Half-life: ~6 days, supporting weekly dosing.

Potential Side Effects

Primarily gastrointestinal (GI) and dose-related, similar to but potentially more pronounced than other GLP-1/GIP therapies due to the glucagon component:

• Common: Nausea, vomiting, diarrhea, constipation, abdominal pain (mostly mild-moderate, peaking early and often improving with time or slower titration).
• Other: Dose-dependent increases in heart rate (peaks around 24 weeks, then declines), potential injection-site reactions, headache, or fatigue.
• Safety Profile: Generally manageable in trials; GI events partially mitigated by lower starting doses. Long-term data still emerging, with no major new safety signals in recent Phase 3 reports.

Note: Retatrutide is experimental and available only through clinical trials or (rarely) off-label/compounded sources in some contexts—quality and safety vary significantly outside regulated channels. Evidence is promising from NEJM-published Phase 2 and recent Phase 3 topline results, but full approval awaits completion of the TRIUMPH program (multiple trials for obesity, diabetes, CV/kidney outcomes, etc.).

Always consult a healthcare professional for personalized advice—peptides like this require monitoring (e.g., labs for glucose, lipids, heart rate), and they’re not substitutes for lifestyle changes. Compared to peptides you’ve asked about before (e.g., Semax/Selank for neuro, Sermorelin for GH, or KPV for anti-inflammatory), Retatrutide is distinctly metabolic/weight-focused in the incretin class. Let me know if you’d like trial updates, comparisons to tirzepatide/semaglutide, or details on nasal/injectable formats!